Ampio initiates clinical trial of Optina in DME, first patient dosed Ampio Pharmaceuticals announced oral dosing of the first patient in a 505b2 clinical trial of the investigational drug Optina in diabetic macular edema, or DME. The trial will evaluate Optina in adults with recent onset diabetic macular edema. Last year, the FDA granted Optina 505b2 status and drugs designated under this pathway can be approved on a single trial.
News For AMPE From The Last 14 Days
Check below for free stories on AMPE the last two weeks.